ANKET

SAR'579 / IPH6101 Granted FDA Fast Track Designation for Hematological Malignancies

SAR’579/IPH6101 Granted FDA Fast Track Designation for Hematological Malignancies

SG Tylor

Source: Innate Pharma On June 6, 2023, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ...

Innate Pharma Showcases Breakthrough Tetra-Specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress

Innate Pharma Showcases Breakthrough Tetra-Specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress

SG Tylor

Source: Innate Pharma On June 10, 2023, Innate Pharma, a biopharmaceutical company, highlights the latest preclinical findings on IPH6501, a ...